Table 1.

Participants’ background and clinical characteristics (n=236)

Characteristics	Total, n (%)	Breast, n (%)	Colorectal, n (%)	Lung, n (%)	Reproductive, n (%)	Head and neck
No./Type of cancer survivors l	236	90 (38.1)	50 (21.2)	20 (8.5)	50 (21.2)	26 (11.0)
Age (years)
30-45	33 (14.0)	20 (22.2)	2 (4.0)	1 (5.0)	8 (16.0)	2 (7.7)
46-60	125 (53.0)	51 (56.7)	22 (44.0)	10 (50.0)	28 (56.0)	14 (53.8)
61-75	63 (26.7)	17 (18.9)	21 (42.0)	7 (35.0)	10 (20.0)	8 (30.8)
Older than 75	15 (6.4)	2 (2.2)	5 (10.0)	2 (10.0)	4 (8.0)	2 (7.7)
Mean±SD	57.1±10.3	54.1±9.8	61.8±9.2	55.9±10.6	58.0±10.4	60.5±10.1
Gender
Male	63 (26.7)	0 (0.0)	29 (58.0)	13 (65.0)	0 (0.0)	21 (80.8)
Female	173 (73.3)	90 (100.0)	21 (42.0)	7 (35.0)	50 (100.0)	5 (19.2)
Length of survival (years)
Not >1	43 (18.2)	18 (20.0)	6 (12.0)	4 (20.0)	6 (12.0)	9 (34.6)
1-5	153 (64.8)	56 (62.2)	34 (68.0)	14 (70.0)	34 (68.0)	15 (57.7)
>5	40 (16.9)	16 (17.8)	10 (20.0)	2 (10.0)	10 (20.0)	2 (7.7)
Mean±SD	3.4±2.5	3.5±2.5	3.5±2.3	4.0±3.0	2.3±1.6	2.8±1.8
Treatment (>1 answer possible)
Chemotherapy	215 (91.1)	85 (94.4)	47 (94.0)	19 (95.0)	45 (90.0)	19 (73.1)
Surgery	158 (66.9)	87 (96.7)	48 (96.0)	4 (20.0)	11 (22.0)	8 (30.8)
Radiotherapy	144 (61.0)	144 (61.0)	50 (55.6)	18 (36.0)	44 (88.0)	26 (100.0)
Hormone therapy	55 (23.3)	54 (60.0)	0 (0.0)	0 (0.0)	1 (2.0)	55 (23.3)
Number of treatment
1	30 (12.7)	4 (4.4)	5 (10.0)	13 (65.0)	5 (10.0)	3 (11.5)
2	108 (45.8)	17 (18.9)	27 (54.0)	5 (25.0)	40 (80.0)	19 (73.1)
3	66 (28.0)	38 (42.2)	18 (36.0)	2 (10.0)	4 (8.0)	4 (15.4)
4	32 (13.6)	31 (34.4)	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)
Mean±SD	2.4±0.9	3.1±0.8	2.3±0.6	1.5±0.7	2.0±0.5	2.0±0.5

SD: Standard deviation